33 related articles for article (PubMed ID: 21043903)
1. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
[TBL] [Abstract][Full Text] [Related]
2. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor.
Coller BS; Peerschke EI; Seligsohn U; Scudder LE; Nurden AT; Rosa JP
J Lab Clin Med; 1986 Apr; 107(4):384-92. PubMed ID: 2420911
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
4. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
5. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention].
Kakuta T; Kishi Y; Numano F
Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330
[TBL] [Abstract][Full Text] [Related]
6. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group.
Bernardi MM; Califf RM; Kleiman N; Ellis SG; Topol EJ
Am J Cardiol; 1993 Nov; 72(15):1121-5. PubMed ID: 8237799
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions.
Knight DM; Wagner C; Jordan R; McAleer MF; DeRita R; Fass DN; Coller BS; Weisman HF; Ghrayeb J
Mol Immunol; 1995 Nov; 32(16):1271-81. PubMed ID: 8559151
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
Jin F; Tayab ZR; Balthasar JP
AAPS J; 2006 Jan; 7(4):E895-902. PubMed ID: 16594642
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Implications of a Specific Murine Monoclonal Antibody (7E3) to the Platelet Receptor GPIIb/IIIa.
Bhattacharya S; Machin SJ; Lahiri A
Platelets; 1992; 3(3):119-24. PubMed ID: 21043903
[TBL] [Abstract][Full Text] [Related]
10. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
[TBL] [Abstract][Full Text] [Related]
11. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
[TBL] [Abstract][Full Text] [Related]
12. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins.
Liu CZ; Hur BT; Huang TF
Thromb Haemost; 1996 Oct; 76(4):585-91. PubMed ID: 8903000
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
[TBL] [Abstract][Full Text] [Related]
14. Anti-GPIIb/IIIa drugs: current strategies and future directions.
Coller BS
Thromb Haemost; 2001 Jul; 86(1):427-43. PubMed ID: 11487034
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
